To include your compound in the COVID-19 Resource Center, submit it here.

Talecris takeout, again

$3.4B Grifols-Talecris deal is windfall for Cerberus chief

Talecris takeout, again

Investors in the October 2009 IPO by Talecris Biotherapeutics Inc. (NASDAQ:TLCR) will get their initial investment back in cash, plus a bit tacked on in shares, under a takeout bid from fellow plasma company Grifols S.A. (Madrid:


Last week, Grifols said it would acquire Talecris for $19 in

Read the full 509 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers